This information was published on 2026-03-16T13:20:33 for IP Right Filed Published.
| Field | Value |
| (210) | 2635972 |
| (220) |
16 Mar 2026
|
| (300) |
US, 07 Jan 2026, 99583006
|
| (511) (510) |
Class 5
Cells for medical or clinical use in the field of gene therapy for the treatment of cardiovascular diseases and thromboembolic diseases and disorders; pharmaceutical and biopharmaceutical agents for the treatment of cardiovascular diseases and thromboembolic diseases and disorders in the field of gene therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cardiovascular diseases and thromboembolic diseases and disorders in the field of gene therapy Class 42 Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of gene therapy |
| (540) | CTX611 |
| (550) | Word |
| (730) |
CRISPR Therapeutics AG
|
| (750) |
Griffith Hack
|
Find out more about publications on the About page.